Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Lori Julin Wirth, M.D.

TitleAssistant Professor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Hem/Onc, Yawkey 7
55 Fruit St
Boston MA 02114
Phone617/724-4000

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
    View in: PubMed
  2. Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI, Stephenson JJ, Wirth LJ, McCoy S, Hei YJ, Hsu CP, Tebbutt NC. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer. 2013; 13:242.
    View in: PubMed
  3. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013 May; 6(5):410-8.
    View in: PubMed
  4. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013 Apr; 23(4):392-407.
    View in: PubMed
  5. Wirth LJ, Ross DS, Randolph GW, Cunnane ME, Sadow PM. Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid. N Engl J Med. 2013 Feb 14; 368(7):664-73.
    View in: PubMed
  6. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90.
    View in: PubMed
  7. Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC. Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer. N Engl J Med. 2012 Sep 20; 367(12):1136-47.
    View in: PubMed
  8. Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report. Anticancer Res. 2012 May; 32(5):1743-6.
    View in: PubMed
  9. Houvras Y, Wirth LJ. Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease. J Clin Oncol. 2011 Jul 1; 29(19):2616-8.
    View in: PubMed
  10. Sher DJ, Balboni TA, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 1; 80(5):1405-11.
    View in: PubMed
  11. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74.
    View in: PubMed
  12. Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
    View in: PubMed
  13. Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, Wirth LJ. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol. 2010 Aug 10; 28(23):e390-2.
    View in: PubMed
  14. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30.
    View in: PubMed
  15. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-7.
    View in: PubMed
  16. Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 1; 115(19):4514-23.
    View in: PubMed
  17. Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
    View in: PubMed
  18. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10; 27(23):3794-801.
    View in: PubMed
  19. Fogg MH, Wirth LJ, Posner M, Wang F. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2009 Mar 3; 106(9):3318-23.
    View in: PubMed
  20. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
    View in: PubMed
  21. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
    View in: PubMed
  22. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
    View in: PubMed
  23. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48.
    View in: PubMed
  24. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3; 359(1):31-42.
    View in: PubMed
  25. Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
    View in: PubMed
  26. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23.
    View in: PubMed
  27. Wirth LJ, Posner MR. Recent advances in combined modality therapy for locally advanced head and neck cancer. Curr Cancer Drug Targets. 2007 Nov; 7(7):674-80.
    View in: PubMed
  28. Freedman RA, Wirth LJ, Chirieac LR, Huang EC. Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol. 2007 Jul 1; 25(19):2848-50.
    View in: PubMed
  29. Freedman RA, Chirieac LR, Huang EC, Wirth LJ. Glioblastoma in a Patient With Early-Stage Tonsil Cancer. Journal of Clinical Oncology. 2007; 25(19):2848-50.
  30. Mager DL, Haddad RI, Wirth LJ, Haffajee AD. Oral Mucous Membrane Macrobiotica in Health and Oral Squamous Cell Carcinoma. Grand Rounds in Oral-Systemic Medicine. 2007; 2(1):12-8.
  31. Wirth L and Kies M. Nonsurgical Treatment for Laryngeal Carcinoma. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  32. Allen A, Posner M, Haddad R, Wirth L, Burke E, Goguen L, Norris C, Annino D, Tishler R. Swallowing function after IMRT and chemotherapy for head and neck cancer. Proc Am Soc Clin Oncol. 2007; 25(18S):Abstr #6046.
  33. Sherman S, Schlumberger M, Droz JP, Hofmann M. Wirth L, Bastholt, L, Martins R, Licitra L, Shi Y, Stepan D. Initial Results from a Phase 2 Trial of AMG 706 in Patients (pts) with Differentiated Thyroid Cancer (DTC). Proc European Thyroid Association. 2007; 8.
  34. Pacini F, Sherman S, Schlumberger M, Elisei R, Wirth L, Bastholt L, Droz JP, Martins R, Hofmann M, Locati L, Eschenberg M, Stepan D. Exacerbation of Postsurgica; Hypothyroidism During Treatment of Advanced Differentiated (DTC) or Medullary (MTC) Thyroid Carcinoma with AMG 706. Proc European Thyroid Association. 2007; 73.
  35. Sherman SI, Schlumberger MJ, Droz J, Hofmann M, Wirth L, Bastholt L, Martins RG, Licitra L, Shi Y, Stepan DE. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). Proc Am Soc Clin Oncol. 2007; 25(18S):Abstr #6017.
  36. Wirth L and Kies M. Treatment of Recurrent and/or Metastatic Head and Neck Cancer. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  37. Schlumberger M, Elisei R, Sherman S, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Sun Y-N, Stepan D. Initial Results froma Phase 2 Trial of Motesanib Diphosphate (AMG 706) in Patients (pts) with Medullary Thyroid Carcinoma (MTC). ENDO Society 2007. 2007; Abstr #852315.
  38. Wirth L and Kies M. Adjuvant Chemoradiotherapy for High-Risk Head and Neck Cancer. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  39. Schlumberger M, Elisei R, Sherman S, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Sun Y-N, Stepan D. Initial Results from a Phase 2 Trial of AMG 706 in Patients (pts) with Medullary Thyroid Cancer (MTC). Proc European Thyroid Association. 2007; 10.
  40. Sherman SI, Schlumberger MJ, Elisei R, Wirth L, Bastholt L, Droz J, Martins RG, Hofmann M, Locati L, Pacini F, Eschenberg MJ, and Stepan D. Exacerbation of Postsurgical Hypothyroidism During Treatment of Thyroid Carcinoma with Motesanib Diphosphate (AMG 706). ENDO Society 2007. 2007; Abstr #850533.
  41. Wirth L and Kies M. Chemoradiotherapy for Locally-Advanced Head and Neck Cancer. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  42. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Goguen LA, Clark JR, Allen AM. Phase I study of panitumumab, chemotherapy, and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. Proc Am Soc Clin Oncol. 2007; 25(18S):Abstr #6083.
  43. Wirth L, Allen AM, Machtay M. Altered fractionation: a fractional benefit? Lancet. 2006 Sep 2; 368(9538):819-21.
    View in: PubMed
  44. Haddad R, Wirth L, Posner M. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7.
    View in: PubMed
  45. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
    View in: PubMed
  46. Goguen LA, Posner MR, Norris CM, Tishler RB, Wirth LJ, Annino DJ, Gagne A, Sullivan CA, Sammartino DE, Haddad RI. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
    View in: PubMed
  47. Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case M, Stowell S, Sammartino D, Busse PM, Haddad RI. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
    View in: PubMed
  48. Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
    View in: PubMed
  49. Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
    View in: PubMed
  50. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med. 2006 Feb 9; 354(6):634-6.
    View in: PubMed
  51. Haddad R, Allen A, Wirth L, Tishler R, Posner M. Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
    View in: PubMed
  52. Posner MR, Haddad RI, Wirth, LJ. The evolution of induction chemotherapy and sequential therapy for locally advanced squamous cell cancer of the head and neck. ASCO Educational Booklet ASCO Atlanta Georgia. 2006; 346-52.
  53. Marshall R. Posner, Robert I. Haddad, and Lori J. Wirth. The evolution of Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Society of Clinical Oncology Education Book. 2006; 42d Annual Meeting:346-353.
  54. Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 1; 23(28):6976-81.
    View in: PubMed
  55. Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
    View in: PubMed
  56. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6.
    View in: PubMed
  57. Jati A, Fennesey F, Wirth L, Jacobsen F. Radiographic characteristics of Typical and Atypical Pulmonary Carcinoids: A Single Institution Retrospective Review. Radiological Society of North America. 2005.
  58. Wirth LJ, Moran AE, Krane JF, Weeks L, Norris, CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM . Pilot Study of Celecoxib in Oral Premalignant Lesions (OPLs): Preliminary Results. Proc Am Soc Clin Oncol. 2005; 348.
  59. Posner MR, Wirth L, Tishler RB, Norris CM, Haddad RI. The evolution of induction chemotherapy in locally advanced squamous cell cancer of the head and neck: New paradigm of sequential therapy. DJ Adelstein, editor. Current Clinical Oncology: Squamous Cell Head and Neck Cancer. 2005; 171-186.
  60. Wirth LJ, Moran AE, Krane JF, Weeks L, Norris CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM. Pilot Study of Celecoxib in Oral Premalignant Lesions (OPLs): Preliminary Results. Proc Am Soc Clin Oncol. 2005; 23(16S):Abstr #1025 .
  61. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
    View in: PubMed
  62. Sullivan CA, Jaklitsch MT, Haddad R, Goguen LA, Gagne A, Wirth LJ, Posner MR, Tishler RB, Norris CM. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
    View in: PubMed
  63. Wirth LJ, Carter MR, Jänne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004 May; 44(2):213-20.
    View in: PubMed
  64. Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8.
    View in: PubMed
  65. Wirth LJ, Haddad RI, Posner MR. Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55.
    View in: PubMed
  66. Haddad RI, Wirth L, Posner MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8.
    View in: PubMed
  67. Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res. 2003 May; 9(5):1698-704.
    View in: PubMed
  68. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
    View in: PubMed
  69. Kolodner RD, Hall NR, Lipford J, Kane MF, Rao MR, Morrison P, Wirth L, Finan PJ, Burn J, Chapman P. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. Genomics. 1994 Dec; 24(3):516-26.
    View in: PubMed
  70. Kolodner RD, Hall NR, Lipford J, Kane MF, Rao MR, Morrison P, Wirth L, Finan PJ, Burn J, Chapman P, et al. Human mismatch repair genes and their association with hereditary non-polyposis colon cancer. Cold Spring Harb Symp Quant Biol. 1994; 59:331-8.
    View in: PubMed
  71. Adra CN, Ko J, Leonard D, Wirth LJ, Cerione RA, Lim B. Identification of a novel protein with GDP dissociation inhibitor activity for the ras-like proteins CDC42Hs and rac I. Genes Chromosomes Cancer. 1993 Dec; 8(4):253-61.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Wirth's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_